This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Randomized Controlled Trial

. 2007 Dec 15;370(9604):2002; author reply 2003-4.

doi: 10.1016/S0140-6736(07)61858-3.

Dabigatran versus enoxaparin after total hip replacement

Christoph Pechlaner, Peter Marschang

PMID: 18083398
DOI: 10.1016/S0140-6736(07)61858-3

Randomized Controlled Trial

Dabigatran versus enoxaparin after total hip replacement

Christoph Pechlaner et al. Lancet. 2007.

. 2007 Dec 15;370(9604):2002; author reply 2003-4.

doi: 10.1016/S0140-6736(07)61858-3.

Authors

Christoph Pechlaner, Peter Marschang

PMID: 18083398
DOI: 10.1016/S0140-6736(07)61858-3

No abstract available

PubMed Disclaimer

Comment on

Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Eriksson BI, et al. Lancet. 2007 Sep 15;370(9591):949-56. doi: 10.1016/S0140-6736(07)61445-7. Lancet. 2007. PMID: 17869635 Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information